Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians

Bipolar Disorders

Volumn 20, Issue 3, 2018, Pages 184-194

  Miskowiak, K W ^a,b   Burdick, K E ^c   Martinez Aran, A ^d   Bonnin, C M ^d   Bowie, C R ^e   Carvalho, A F ^f   Gallagher, P ^g   Lafer, B ^h   Lopez Jaramillo C ⁱ   Sumiyoshi, T ^j   McIntyre, R S ^k   Schaffer, A ^k   Porter, R J ^l   Purdon, S ^m   Torres, I J ⁿ   Yatham, L N ⁿ   Young, A H ^o   Kessing, L V ^a   Vieta, E ^d  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e QUEEN S UNIVERSITY   (Canada)

^f FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^j NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY OF OTAGO   (New Zealand)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

bipolar disorder; cognitive impairment; neuropsychological; recommendations; screening

Indexed keywords

BIPOLAR DISORDER; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSESSMENT; E-MAIL; EVIDENCE BASED PRACTICE; HUMAN; NEUROPSYCHOLOGY; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING TEST; TELEPHONE INTERVIEW; COGNITIVE RESERVE; CONSENSUS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; COGNITIVE RESERVE; CONSENSUS; HUMANS; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 85046546214     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12595     Document Type: Review

References (73)

1. The WHOQOL group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403-1409.
2. Glahn DC, Bearden CE, Bowden CL, Soares JC. Reduced educational attainment in bipolar disorder. J Affect Disord. 2006;92:309-312.
3. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002;63:120-125.
4. Marwaha S, Durrani A, Singh S. Employment outcomes in people with bipolar disorder: a systematic review. Acta Psychiatr Scand. 2013;128:179-193.
5. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 2007;9:183-196.
6. Kogan JN, Otto MW, Bauer MS, et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 2004;6:460-469.
7. Decker L, Träger C, Miskowiak K, Waehrens E, Vinberg M. Ability to perform Activities of Daily Living among patients with bipolar disorder in remission. Edorium J Disability Rehabilitation 2017;3:69-79.
8. Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016;15:288-289.
9. Mackala SA, Torres IJ, Kozicky J, Michalak EE, Yatham LN. Cognitive performance and quality of life early in the course of bipolar disorder. J Affect Disord. 2014 Oct;168:119-124.
10. Bonnin CM, Martinez-Aran A, Torrent C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121:156-160.
11. Martinez-Aran A, Vieta E, Torrent C, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9:103-113.
12. Torrent C, Martinez-Aran A, del Mar BC, et al. Long-term outcome of cognitive impairment in bipolar disorder. J Clin Psychiatry. 2012;73:e899-e905.
13. Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16:217-229.
14. Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14:217-226.
15. Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128:149-162.
16. Burdick KE, Russo M, Frangou S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44:3083-3096.
17. Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. J Affect Disord. 2016;15:378-386.
18. Sole B, Jimenez E, Torrent C, et al. Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved. Bipolar Disord. 2016;18:288-299.
19. Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder. J Affect Disord. 2016;205:378-386.
20. Miskowiak K, Burdick K, Martinez-Aran A, et al. Methodological recommendations for cognition trials in bipolar disorder by the international society for bipolar disorders targeting cognition task force. Bipolar Disord. 2017;19:614-626.
21. Yatham LN, Torres IJ, Malhi GS, et al. The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC). Bipolar Disord. 2010;12:351-363.
22. Burdick KE, Endick CJ, Goldberg JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res. 2005;15:43-50.
23. Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Assessment of subjective and objective cognitive function in bipolar disorder: correlations, predictors and the relation to psychosocial function. Psychiatry Res. 2015;30:565-571.
24. Jensen JH, Støttrup MM, Nayberg E, et al. Optimising screening for cognitive dysfunction in bipolar disorder: validation and evaluation of objective and subjective tools. J Affect Disord. 2015;187:19.
25. Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry. 2012;66:248-253.
26. Miskowiak KW, Petersen JZ, Ott CV, et al. Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. Acta Psychiatr Scand. 2016;134:511-521.
27. Van Camp LS, Oldenburg JF, Sabbe BG. How self-reflection and self-certainty are related to neurocognitive functioning: an examination of cognitive insight in bipolar disorder. Cogn Neuropsychiatry. 2016;21:130-145.
28. Li Y, Root JC, Atkinson TM, Ahles TA. Examining the association between patient-reported symptoms of attention and memory dysfunction with objective cognitive performance: a latent regression rasch model approach. Arch Clin Neuropsychol. 2016;31:365-377.
29. Yen CF, Cheng CP, Ko CH, Yen JY, Huang CF, Chen CS. Relationship between insight and neurocognition in patients with bipolar I disorder in remission. Compr Psychiatry. 2008;49:335-339.
30. Grande I, Berk M, Birmaher B, Vieta E Bipolar disorder. Lancet 2016;388:869-870.
31. Mago R, Borra D, Mahajan R. Role of adverse effects in medication nonadherence in bipolar disorder. Harv Rev Psychiatry. 2014;22:363-366.
32. Duff K. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol. 2012;27:248-261.
33. Purdon S. The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties. Alberta, Canada, Edmonton; 2005.
34. Rosa AR, Mercade C, Sanchez-Moreno J, et al. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J Affect Disord. 2013;15:29-36.
35. Rojo E, Pino O, Guilera G, et al. Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). Schizophr Res. 2010;116:243-251.
36. Toyoshima K, Fujii Y, Mitsui N, et al. Validity and reliability of the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) in Japanese patients with bipolar disorder. Psychiatry Res. 2017;254:85-89.
37. Xiao L, Lin X, Wang Q, Lu D, Tang S. Adaptation and validation of the “cognitive complaints in bipolar disorder rating assessment” (COBRA) in Chinese bipolar patients. J Affect Disord. 2015;173:226-231.
38. Malhi GS, McAulay C, Gershon S, et al. The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord. 2016;18:102-115.
39. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29:737-752.
40. Gualtieri CT, Johnson LG. Age-related cognitive decline in patients with mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008;15:962-967.
41. Chen MH, Li CT, Tsai CF, et al. Risk of subsequent dementia among patients with bipolar disorder or major depression: a nationwide longitudinal study in Taiwan. J Am Med Dir Assoc. 2015;16:504-508.
42. da SJ, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry 2013;202:177-186.
43. Rej S, Quayle W, Forester BP, et al. Measurement tools for assessment of older age bipolar disorder: a systematic review of the recent global literature. Bipolar Disord 2017. [Epub ahead of print]. https://doi.doi/10.1111/bdi.12566
44. Roebuck-Spencer TM, Glen T, Puente AE, et al. Cognitive screening Tests versus comprehensive neuropsychological test batteries: a national academy of neuropsychology education paperdagger. Arch Clin Neuropsychol. 2017;32:491-498.
45. Miskowiak KW, Ott CV, Petersen JZ, Kessing LV. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. Eur Neuropsychopharmacol 2016;26:1845-1867.
46. Lewandowski KE, Sperry SH, Cohen BM, et al. Treatment to Enhance Cognition in Bipolar Disorder (TREC-BD): Efficacy of a Randomized Controlled Trial of Cognitive Remediation Versus Active Control. J Clin Psychiatry 2017. [Epub ahead of print]. https://doi.org/10.4088/JCP.17m11476.
47. Grande I, Sanchez-Moreno J, Sole B, et al. High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. J Affect Disord. 2017;208:621-627.
48. Stern RA, Silva SG, Chaisson N, Evans DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol. 1996;53:148-153.
49. Forcada I, Mur M, Mora E, Vieta E, Bartres-Faz D, Portella MJ. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. Eur Neuropsychopharmacol. 2015;25:214-222.
50. Watson S, Gallagher P, Porter RJ, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry. 2012;72:943-949.
51. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29:1538-1545.
52. Yatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry 2017;4:208-217.
53. Miskowiak KW, Vinberg M, Christensen EM, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology. 2014;39:1399-1408.
54. Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry 2014;75:1347-1355.
55. Ott CV, Vinberg M, Kessing LV, Miskowiak KW. The effect of erythropoietin on cognition in affective disorders - Associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 2016;26:1264-1273.
56. Kaser M, Deakin J, Michael A, et al. Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: a Double-Blind, Randomized, Placebo-Controlled Study. Biol. Psychiatry CNNI 2017;2:115-122.
57. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016;19:1-9.
58. Smith J, Browning M, Conen S, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2017:1-7.
59. Torrent C, Bonnin CM, Martinez-Aran A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170:852-859.
60. Bonnin CM, Torrent C, Arango C, et al. Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. Br J Psychiatry. 2016;208:87-93.
61. Bonnin CM, Reinares M, Martinez-Aran A, et al. Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychol Med 2016;46:291-301.
62. Deckersbach T, Nierenberg AA, Kessler R, et al. RESEARCH: cognitive rehabilitation for bipolar disorder: an open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther. 2010;16:298-307.
63. Meusel LA, Hall GB, Fougere P, McKinnon MC, MacQueen GM. Neural correlates of cognitive remediation in patients with mood disorders. Psychiatry Res. 2013;214:142-152.
64. Naismith SL, Redoblado-Hodge MA, Lewis SJ, Scott EM, Hickie IB. Cognitive training in affective disorders improves memory: a preliminary study using the NEAR approach. J Affect Disord. 2010;121:258-262.
65. Preiss M, Shatil E, Cermakova R, Cimermanova D, Ram I. Personalized cognitive training in unipolar and bipolar disorder: a study of cognitive functioning. Front Hum. Neurosci. 2013;7:108.
66. Veeh J, Kopf J, Kittel-Schneider S, Deckert J, Reif A. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. Int. J. Bipolar. Disord. 2017;5:8.
67. Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. PLoS ONE. 2015;10:e0127955.
68. Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based cognitive remediation for individuals with serious mental illnesses: effects of real-world simulations and goal setting on functional and vocational outcomes. Psychiatr Rehabil J. 2017;40:53-60.
69. Ott C, Vinberg M, Bowie C, Christensen E, Kessing LV, Miskowiak K. Effect of Action-Based Cognitive Remediation on cognition and neural activity in bipolar disorder and healthy first-degree relatives: study protocol for a randomised controlled trial. Trials 2017. in press.
70. Gomes BC, Rocca CC, Belizario GO, Lafer B. Cognitive-behavioral rehabilitation vs. treatment as usual for bipolar patients: study protocol for a randomized controlled trial. Trials. 2017;18:142.
71. Strawbridge R, Fish J, Halari R, et al. The Cognitive Remediation in Bipolar (CRiB) pilot study: study protocol for a randomised controlled trial. Trials. 2016;17:371.
72. Lewandowski KE, Sperry SH, Ongur D, Cohen BM, Norris LA, Keshavan MS. Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial. Trials. 2016;17:136.
73. Breitborde NJ, Dawson SC, Woolverton C, et al. A randomized controlled trial of cognitive remediation and d-cycloserine for individuals with bipolar disorder. BMC Psychol. 2014;2:41.